Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Christopher Richard Anzalone net worth and biography

Christopher Anzalone Biography and Net Worth

CEO of Arrowhead Pharmaceuticals

Dr. Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. In 2005, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring, and building new business ventures. Prior to Galway, Dr. Anzalone was an NIH-supported post doctoral fellow in Reproductive Endocrinology at the Smithsonian Institution’s Conservation and Research Center. Dr. Anzalone holds a Ph.D. in Biology from UCLA and a B.A. in Government from Lawrence University.

What is Christopher Richard Anzalone's net worth?: The estimated net worth of Christopher Richard Anzalone is at least $69.51 million as of January 31st, 2024. Dr. Anzalone owns 3,715,048 shares of Arrowhead Pharmaceuticals stock worth more than $69,508,548 as of November 20th. This net worth evaluation does not reflect any other assets that Dr. Anzalone may own. Additionally, Dr. Anzalone receives a salary of $1,600,000.00 as CEO at Arrowhead Pharmaceuticals. Learn More about Christopher Richard Anzalone's net worth.
How old is Christopher Richard Anzalone?: Dr. Anzalone is currently 55 years old. There are 6 older executives and no younger executives at Arrowhead Pharmaceuticals. Learn More on Christopher Richard Anzalone's age.
What is Christopher Richard Anzalone's salary?: As the CEO of Arrowhead Pharmaceuticals, Inc., Dr. Anzalone earns $1,600,000.00 per year. Learn More on Christopher Richard Anzalone's salary.
How do I contact Christopher Richard Anzalone?: The corporate mailing address for Dr. Anzalone and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Christopher Richard Anzalone's contact information.
Has Christopher Richard Anzalone been buying or selling shares of Arrowhead Pharmaceuticals?: Christopher Richard Anzalone has not been actively trading shares of Arrowhead Pharmaceuticals within the last three months. Most recently, Christopher Richard Anzalone sold 57,499 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $32.35, for a transaction totalling $1,860,092.65. Following the completion of the sale, the chief executive officer now directly owns 3,715,048 shares of the company's stock, valued at $120,181,802.80. Learn More on Christopher Richard Anzalone's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 14 times. They sold a total of 247,332 shares worth more than $8,158,854.05. The most recent insider tranaction occured on July, 2nd when insider Tracie Oliver sold 9,394 shares worth more than $237,480.32. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 7/2/2024.

Christopher Richard Anzalone Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/31/2024	Sell	57,499	$32.35	$1,860,092.65	3,715,048
1/2/2024	Sell	9,952	$31.01	$308,611.52	3,715,048
12/20/2023	Sell	12,000	$28.54	$342,480.00	3,725,000
10/25/2023	Sell	24,338	$24.21	$589,222.98	3,737,000
9/18/2023	Sell	57,755	$28.12	$1,624,070.60	3,761,338
5/3/2023	Sell	54,928	$39.14	$2,149,881.92	3,761,338
2/11/2022	Sell	146,388	$51.91	$7,599,001.08
12/15/2021	Sell	60,000	$67.56	$4,053,600.00
10/22/2021	Sell	50,000	$65.63	$3,281,500.00
10/20/2021	Sell	15,000	$66.23	$993,450.00
12/9/2020	Sell	38,676	$69.06	$2,670,964.56	2,521,561
10/23/2020	Sell	100,000	$58.21	$5,821,000.00
8/13/2020	Sell	50,000	$41.35	$2,067,500.00	2,655,237
6/25/2020	Sell	100,000	$38.81	$3,881,000.00	2,605,260
12/12/2019	Sell	100,000	$67.50	$6,750,000.00	2,048,684
12/2/2019	Sell	37,967	$69.15	$2,625,418.05	2,116,160
10/10/2019	Sell	56,325	$31.83	$1,792,824.75	2,178,228
9/24/2019	Sell	66,645	$28.20	$1,879,389.00	2,146,153
9/20/2019	Sell	4,250	$29.00	$123,250.00	2,146,153
4/3/2019	Sell	50,000	$19.30	$965,000.00
12/19/2018	Sell	90,000	$13.92	$1,252,800.00
12/12/2018	Sell	90,000	$14.07	$1,266,300.00
11/9/2018	Sell	81,500	$14.39	$1,172,785.00	1,727,755
9/4/2018	Sell	164,834	$14.45	$2,381,851.30	1,868,789
8/31/2018	Sell	100,000	$14.45	$1,445,000.00	1,868,789
3/15/2018	Sell	300,000	$7.43	$2,229,000.00	2,194,789
3/13/2018	Sell	100,000	$7.43	$743,000.00	2,194,789
10/15/2014	Buy	16,000	$6.32	$101,120.00

Christopher Richard Anzalone Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $18.71

$18.04

$18.75

50 Day Range

MA: $19.96

$17.70

$21.97

2 Week Range

Now: $18.71

$17.05

$39.83

Volume

792,142 shs

Average Volume

1,199,403 shs

Market Capitalization

$2.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

Christopher Anzalone Biography and Net Worth

What is Christopher Richard Anzalone's net worth?

How old is Christopher Richard Anzalone?

What is Christopher Richard Anzalone's salary?

How do I contact Christopher Richard Anzalone?

Has Christopher Richard Anzalone been buying or selling shares of Arrowhead Pharmaceuticals?

Who are Arrowhead Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Arrowhead Pharmaceuticals?